Herpes labialis

Aug 05, 2019

Squarex Announces Positive Results from Completed Phase 2 Study of SQX770 in the Prevention of Recurrent Herpes Labialis

Jul 01, 2019

Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer

May 29, 2019

Squarex to Present at 2019 BIO International Convention

Feb 27, 2019

NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering

Feb 14, 2019

Squarex Announces Publication of Clinical Results for SQX770 for the Prevention of Herpes Outbreaks in Immunity, Inflammation and Disease

Dec 20, 2018

Squarex to Present at Biotech Showcase 2019

Dec 02, 2018

Merix Pharmaceutical Corp. Announces Availability of RELEEV® 1 Day Cold Sore Treatment in Convenience Stores

Nov 26, 2018

NanoViricides Files Quarterly Report for Period Ending September 30, 2018

May 22, 2018

NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates

Mar 23, 2018

Herpes Labialis Treatment Market is Poised to Expand at a Moderate CAGR of 4.6% Over 2017-2027: Future Market Insights

Mar 19, 2018

NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin

Sep 25, 2017

Genital Herpes: Only Scientific Facts on Lilac Corp Website